Dr. Dan Landau

A powerful new analytical tool offers a closer look at how tumor cells “shape-shift” to become more aggressive and untreatable, as shown in a study from researchers at Weill Cornell Medicine and the New York Genome Center.

An artificial intelligence-powered method for detecting tumor DNA in blood has shown unprecedented sensitivity in predicting cancer recurrence, in a study led by researchers at Weill Cornell Medicine, NewYork-Presbyterian, the New York Genome Center and Memorial Sloan Kettering Cancer Center.

A team co-led by researchers at Weill Cornell Medicine and the New York Genome Center has developed an advanced method for revealing how gene mutations disrupt the normal packaging of DNA. 

A technique that enables scientists to record gene mutations and patterns of gene activity in individual cells has been extended to cover RNA splicing as well, in a study led by researchers at Weill Cornell Medicine, the New York Genome Center and the Princess Margaret Cancer Centre in Toronto.

Weill Cornell Medicine has received a grant from the National Institutes of Health (NIH) as part of a new $140 million Common Fund program to study somatic mosaicism, a phenomenon in which organs and tissues develop significant genetic differences across their cell populations.

A new method can illuminate the identities and activities of cells throughout an organ or a tumor at unprecedented resolution.

A common, spontaneous mutation in blood stem cells, which has been linked to higher risks of blood cancer and cardiovascular disease, may promote these diseases by altering the stem cells’ programming of gene activity and the mix of blood cells they produce.

Researchers at Weill Cornell Medicine have identified a key protein that induces the program to build specialized liver blood vessels. The discovery could lead to engineered replacement hepatic tissue to treat common liver diseases.

Awards, honors, prizes and achievements for the month of January.

A team led by researchers at Weill Cornell Medicine, the New York Genome Center, Harvard Medical School, Massachusetts General Hospital and the Broad Institute of MIT and Harvard has profiled in unprecedented detail thousands of individual cells sampled from patients’ brain tumors.

Scientists have made major advances in understanding and developing treatments for many cancers by identifying genetic mutations that drive the disease. Now a team led by researchers at Weill Cornell Medicine, NewYork-Presbyterian and the New York Genome Center (NYGC) has developed a machine learning technique for detecting other modifications to DNA that have a similar effect.

Cancer biologists at Weill Cornell Medicine have been awarded a 2021 Top 10 Clinical Research Achievement Award from the Clinical Research Forum for their study last year describing a highly sensitive blood test for monitoring cancer progression and relapse.

Dr. Dan Landau, an associate professor of medicine and a member of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine, has been awarded a four-year, $600,000 Distinguished Scientist grant by the Sontag Foundation to study the diversity of cell types within brain cancers called gliomas.

Five Weill Cornell Medicine investigators have received funding from the Chan Zuckerberg Initiative (CZI) for their research in inflammation and neurodegenerative disorders.

Dr. Dan Landau, an associate professor of medicine and a member of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center, has been named a 2020 Vallee Scholar by the Vallee Foundation.

A DNA-sequencing strategy powered by machine learning may pick up even very low levels of tumor DNA in blood samples, potentially enabling the early detection of cancer recurrence after surgery or other treatments, according to a study led by scientists at Weill Cornell Medicine and the New York Genome Center (NYGC).

Gene mutations that are thought to be very early events in the development of leukemias and other blood disorders appear to set the stage for malignancy by increasing the production of certain types of blood cells at the expense of others.

A set of powerful laboratory and computational techniques developed by scientists at Weill Cornell Medicine, the New York Genome Center (NYGC) and the Broad Institute will enable investigators to map the capacity of tumors to develop resistance to drugs and drug combinations. 

A new technology devised by scientists at Weill Cornell Medicine and the New York Genome Center (NYGC) enables the measurement of gene mutations and their effects on gene activity within individual cancer cells biopsied from patients.

A powerful new set of scientific tools developed by Weill Cornell Medicine and New York Genome Center (NYGC) researchers enables them to track the molecular evolution of cancers.